

Supplementary online only Table 1. Case-control studies that have evaluated anti-Ro/La titers in affected and non-affected pregnancies with CHB

Author, year (reference)	Study group: mothers of babies with ACHB (n)	Control groups (n)	Antibody (technique)	Positive titers (n, %) or autoantibody levels (mean)	P values (comparison between groups)
Meilof et al, 1993 ³⁷	14	- Mothers of babies with postnatal CHB (10) - Ro+ SLE mothers of unaffected babies (12)	Ro/SS-A (ELISA)	ND	Ro/SS-A < 0,05 (fetal vs postnatal CHB) Ro/SS-A > 0,05 (fetal CHB vs no CHB)
Dörner et al, 1995 ²³	16	- Ro+ SLE mothers of unaffected babies (8)	IgG Ro52, Ro60, La levels (recombinant Immunoblot)	ND	Ro52 < 0,015 , Ro60 > 0,05 and La < 0,015 (CHB vs no CHB)
Silverman et al, 1995 ⁴⁶	21	- Mothers of babies with neonatal rash (20) - Ro+ SAD mothers of unaffected babies (16)	Ro52, La levels (recombinant ELISA)	<i>Ro52 levels (mean): 0,71 vs 0,82 vs 0,29</i> <i>La levels (mean): 0,51 vs 0,83 vs 0,01</i>	Ro52: > 0,05 (CHB vs rash), 0,0006 (CHB vs no CHB) La: 0,009 (CHB vs rash), 0,005 (CHB vs no CHB)
Salomonsson et al, 2002 ⁴³	9	- Ro+ SAD mothers of unaffected babies (26)	IgG Ro52, Ro60, La levels (recombinant ELISA/Western)	ND	Ro52 < 0,02 , Ro60 < 0,02 and La < 0,05 (CHB vs no CHB)
Julkunen et al, 2004 ³⁵	67	- SAD mothers of unaffected babies (136)*	Ro52, Ro60, La levels (recombinant TR-FIA and ELISA)	ND	> 0,05 (CHB vs SS without CHB)** < 0,001 (CHB vs non-SS without CHB)**
Jaeggi et al, 2010 ³³	40	- Ro+ SAD mothers of unaffected babies (146)	Ro52 ≥ 50 U/mL (recombinant ELISA)	40 (100%) vs 64 (44%)	Ro52 < 0,0001 (CHB vs no CHB)
Anami et al, 2012 ¹⁴	17	- Ro+ SAD mothers of unaffected babies (172)	Ro/SS-A ≥ 1:32 (DID, ND)	15 (88%) vs 93 (54%)	Ro/SS-A = 0,01 (CHB vs no CHB)
Reed et al, 2012 ⁵²	50	- SAD mothers with CHB and subsequent unaffected babies (32) - SAD mothers of unaffected babies (33)	Ro52 (full-length ELISA) Ro60 (native) La (purified ELISA)	<i>Ro52 levels (mean): 87 vs 93 vs 75</i> <i>Ro60 levels (mean): 14,336 vs 16,896 vs 2,624</i> <i>La levels (mean): 3,904 vs 1,944 vs 752</i>	Ro52 > 0,05 (all comparisons) Ro60 < 0,05 (CHB/previous CHB vs no CHB) La > 0,05 (all comparisons)
Tunks et al, 2013 ⁴⁸	6	- Ro+ SAD mothers of unaffected babies (27)	Ro/SS-A, La levels (Athena Multi-Lyte ANA-II Plus Test, ND)	<i>Ro levels (mean):</i> No CHB: 496; type I: 443; type II: 520; type III: 520 <i>La levels (mean):</i> No CHB 109, type I 335, type II 128, type III 267	Ro/SS-A = 0,94 (CHB vs no CHB) La = 0,04 (CHB vs no CHB)

ND: Not detailed; TR-FIA: Time-resolved fluoroimmunoassay; DID: Double immune-diffusion; SAD: Systemic autoimmune disease. *Ro+ in only 58% of cases, **titers of the three antibodies

Supplementary online only Table 2. Age of pacemaker implantation detailed in 192 reported cases^{17,21,22,24,25,29,40,68,73,74,78,85,88,102,104,107,108}

Author (reference)	Total number of paced cases (n)	< 10 days (n)	10 days – 1 month (n)	1-12 months (n)	1-5 years (n)	> 5 years (n)
Groves et al, 1996 ²⁹	11	2	2	4	1	2
McLeod et al, 1998 ¹⁰⁷	1	-	-	1	-	-
Eronen et al, 2000 ¹⁰³	6	6	-	-	-	-
Askanase et al, 2002 ¹⁰⁸	5	-	-	-	3	2
Costedoat et al, 2003 ²¹	1	-	-	-	1	-
Costedoat et al, 2004 ²²	1	1	-	-	-	-
Eronen et al, 2004 ⁶⁸	2	1	1	-	-	-
Stevens et al, 2005 ¹⁰⁹	1	-	-	1	-	-
Gardiner et al, 2007 ²⁵	3	1	-	-	2	-
Friedman et al, 2008 ⁷⁸	1	1	-	-	-	-
Brucato et al, 2009 ¹⁷	26	10	6	7	3	-
Chockalingam et al, 2011 ⁷³	1	-	-	-	-	1
Fesslova et al, 2009 ²⁴	22	6	6	7	3	-
Hayashi et al, 2009 ¹⁰²	4	1	1	2	-	-
Friedman et al, 2010 ⁸⁸	2	2	-	-	-	-
Pisoni et al, 2010 ⁴⁰	1	1	-	-	-	-
Trucco et al, 2011 ⁷⁴	12	12	-	-	-	-
Subtotal	100	44 (44%)	16 (16%)	22 (22%)	13 (13%)	5 (5%)
Saleeb et al, 1999 ¹⁰⁴	25	15	6		4	-
Buyon et al, 1998 ⁸⁵	67	35	15		17	
TOTAL	192	94 (49%)	59 (31%)		39 (20%)	

Supplementary online only Table 3. Outcome of babies according to the specific autoantibody maternal profile detailed in 2 prospective studies^{16,28}

Autoantibody maternal profile	Tested mothers (n)	Mothers with positive antibodies n (%)	Babies with CHB from mothers with positive antibodies (%)	CHB types n (CHB type)
Ro+	141	140 (99.3%)	4/140 (2.86)	3 (III). 1 (II)
La+	141	51 (36.17%)	2/51 (3.92)	1 (III). 1 (II)
Ro52+	134	61 (45.52%)	3/61 (4.92)	2 (III). 1 (II)
Ro60+	134	121 (90.3%)	4/121 (3.31)	3 (III). 1 (II)
Combination of antibodies				
Ro and La	141	51 (36.17%)	2/51 (3.92)	1 (III). 1 (II)
Only Ro	141	89 (63.12%)	2/89 (2.25)	2 (III)
Only La	141	1 (0.71%)	0/1 (0)	0